These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 33037532

  • 1. Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review.
    Psomiadou V, Prodromidou A, Fotiou A, Lekka S, Iavazzo C.
    J Robot Surg; 2021 Apr; 15(2):155-163. PubMed ID: 33037532
    [Abstract] [Full Text] [Related]

  • 2. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J, Gotlieb W, Zeng Z, Ramanakumar A, Kessous R, Kogan L, Pare-Miron V, Rombaldi M, Salvador S, Kucukyazici B, Brin S, How J, Lau S.
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [Abstract] [Full Text] [Related]

  • 3. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
    Zhang Y, Grant MS, Zhang X, Paraghamian SE, Tan X, Clark LH.
    J Minim Invasive Gynecol; 2021 Jun; 28(6):1237-1243. PubMed ID: 33248314
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE, Tripcony L, Sanday K, Robertson J, Perrin L, Chetty N, Land R, Garrett A, Obermair A, Nascimento M, Tang A, Jagasia N, Singh P, Nicklin J.
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [Abstract] [Full Text] [Related]

  • 6. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Morton M, Chambers LM, Costales AB, Chichura A, Gruner M, Horowitz MP, Rose PG, Yao M, Debernardo R, Michener C.
    Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
    [Abstract] [Full Text] [Related]

  • 7. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF, Zhang GN, Peng CR, Shi Y, Shi XW.
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun 25; 56(6):385-392. PubMed ID: 34154313
    [Abstract] [Full Text] [Related]

  • 8. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V, Moruzzi MC, Bizzarri N, Vargiu V, D'Indinosante M, Garganese G, Pasciuto T, Loverro M, Scambia G, Fagotti A.
    Gynecol Oncol; 2020 Apr 25; 157(1):209-213. PubMed ID: 31952843
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R, Zhu J, Kim JW, Liu J, Kato K, Kim HS, Zhang Y, Zhang P, Zhu T, Aoki D, Yu A, Chen X, Wang X, Zhu D, Zhang W, Jia H, Shi T, Gao W, Yin S, Feng Y, Xiang L, Okamoto A, Zang R.
    J Gynecol Oncol; 2020 Sep 25; 31(5):e86. PubMed ID: 32808504
    [Abstract] [Full Text] [Related]

  • 14. Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis.
    Chiofalo B, Bruni S, Certelli C, Sperduti I, Baiocco E, Vizza E.
    Minerva Med; 2019 Aug 25; 110(4):330-340. PubMed ID: 31081304
    [Abstract] [Full Text] [Related]

  • 15. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL, Hicks-Courant K, Gockley AA, Clark RM, Del Carmen MG, Growdon WB, Horowitz NS, Berkowitz RS, Muto MG, Worley MJ.
    Am J Obstet Gynecol; 2019 Oct 25; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
    Piedimonte S, Kessous R, Laskov I, Abitbol J, Kogan L, Yasmeen A, Salvador S, Lau S, Gotlieb WH.
    J Obstet Gynaecol Can; 2020 Nov 25; 42(11):1339-1345. PubMed ID: 32859533
    [Abstract] [Full Text] [Related]

  • 18. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
    Gueli Alletti S, Bottoni C, Fanfani F, Gallotta V, Chiantera V, Costantini B, Cosentino F, Ercoli A, Scambia G, Fagotti A.
    Am J Obstet Gynecol; 2016 Apr 25; 214(4):503.e1-503.e6. PubMed ID: 26529370
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.